Answers are grounded in this paper and cite their sources.
Cytotoxic drugs administered during conventional chemotherapy are taken up by sensitive nontarget organs besides the tumor cells and this often leads to unwanted side effects . These problems have initiated studies during the past decade to develop novel methods in which the therapeutic reagents could be directed to specific cell populations to widen the therapeutic window. The concept of targeting drugs was proposed nearly a hundred years ago by Paul Erlich, who envisioned the possibility of transporting toxic substances to tumor cells by carrier molecules (magic bullets). This novel approach became a reality with the advent of tumor selective monoclonal antibodies (Mabs) produced by somatic cell hybridization. Both cytotoxic drugs and toxin polypeptides have been chemically linked to Mabs. During the past decade various molecules have been produced and tested in a number of model systems (reviewed in 1-10). The range of targets includes (a) ex vivo treatment of bone marrow grafts to remove contaminating leukemic cells and alloreactive T cells , (b) administration of conjugates to inhibit tumor growth
No takes yet. Share an insight, caveat, or question.
Ramakrishnan et al. (1992) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: